<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Novartis Ag — News on 6ix</title>
    <link>https://6ix.com/company/novartis-ag</link>
    <description>Latest news and press releases for Novartis Ag on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 28 Apr 2026 05:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/novartis-ag" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68361bec78dffbe2df13f5ee.webp</url>
      <title>Novartis Ag</title>
      <link>https://6ix.com/company/novartis-ag</link>
    </image>
    <item>
      <title>Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed</title>
      <link>https://6ix.com/company/novartis-ag/news/novartis-delivered-strong-growth-in-priority-brands-and-launches-in-q1-fy-2026-guidance-reaffirmed</link>
      <guid isPermaLink="true">https://6ix.com/company/novartis-ag/news/novartis-delivered-strong-growth-in-priority-brands-and-launches-in-q1-fy-2026-guidance-reaffirmed</guid>
      <pubDate>Tue, 28 Apr 2026 05:00:00 GMT</pubDate>
      <description>Ad hoc announcement pursuant to Art. 53 LRFirst quarterNet sales declined -5% (cc1, -1% USD), as growth drivers were more than offset by US generic erosionContinued strong performance from priority brands including Kisqali (+55% cc), Pluvicto (+70% cc), Kesimpta (+26% cc), Scemblix (+79% cc) and Leqvio (+69% cc)Core operating income1 down -14% (cc, -12% USD), due to lower net sales and higher R&amp;D investmentCore operating income margin1 was 37.3%Operating income declined -11% (cc, -9% USD); net i</description>
    </item>
    <item>
      <title>Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria</title>
      <link>https://6ix.com/company/novartis-ag/news/novartis-rhapsidor-receives-european-commission-approval-as-first-oral-targeted-treatment-for-chronic-spontaneous-urticaria</link>
      <guid isPermaLink="true">https://6ix.com/company/novartis-ag/news/novartis-rhapsidor-receives-european-commission-approval-as-first-oral-targeted-treatment-for-chronic-spontaneous-urticaria</guid>
      <pubDate>Mon, 27 Apr 2026 05:15:00 GMT</pubDate>
      <description>Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 &amp; 2 studies of highly selective, oral BTKi1Rhapsido recommended in 2026 International Urticaria Guideline for all patients who remain symptomatic after H1-antihistamine treatment2CSU affects nearly 4 million people in Europe; more than 50% continue to experience debilitating symptoms after conventional antihistamine therapy3-5 Basel, April 27, 2026 – Novartis announced today that the Eur</description>
    </item>
    <item>
      <title>Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)</title>
      <link>https://6ix.com/company/novartis-ag/news/novartis-receives-positive-chmp-opinion-for-itvismar-for-spinal-muscular-atrophy-sma</link>
      <guid isPermaLink="true">https://6ix.com/company/novartis-ag/news/novartis-receives-positive-chmp-opinion-for-itvismar-for-spinal-muscular-atrophy-sma</guid>
      <pubDate>Fri, 24 Apr 2026 10:30:00 GMT</pubDate>
      <description>If approved, Itvisma (intrathecal onasemnogene abeparvovec) will be first and only gene replacement therapy for children two years and older, teens and adults with SMA in the European UnionItvisma demonstrated clinically meaningful and statistically significant improvement in motor function in Phase III STEER studyOne-time dose of Itvisma replaces SMN1 gene, with potential to reduce need for chronic SMA treatment Basel, April 24, 2026 – Novartis today announced that the Committee for Medicinal P</description>
    </item>
    <item>
      <title>Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants</title>
      <link>https://6ix.com/company/novartis-ag/news/novartis-malaria-treatment-coartemr-baby-receives-who-prequalification-paving-way-for-greater-access-for-newborns-and-young-infants</link>
      <guid isPermaLink="true">https://6ix.com/company/novartis-ag/news/novartis-malaria-treatment-coartemr-baby-receives-who-prequalification-paving-way-for-greater-access-for-newborns-and-young-infants</guid>
      <pubDate>Fri, 24 Apr 2026 05:15:00 GMT</pubDate>
      <description>Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap WHO prequalification key milestone for donor-funded and public sector purchasing by UN and other procurement agenciesNovartis making treatment available on largely not-for-profit basis in areas where malaria is endemic East Hanover, April 24, 2026 – Novartis today announced that the World Health Organization (WHO) has prequalified Coartem® (artemethe</description>
    </item>
    <item>
      <title>Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030</title>
      <link>https://6ix.com/company/novartis-ag/news/novartis-announces-expansion-of-community-health-programs-to-close-gaps-in-heart-disease-and-cancer-care-targeting-more-than-30-countries-by-2030</link>
      <guid isPermaLink="true">https://6ix.com/company/novartis-ag/news/novartis-announces-expansion-of-community-health-programs-to-close-gaps-in-heart-disease-and-cancer-care-targeting-more-than-30-countries-by-2030</guid>
      <pubDate>Thu, 09 Apr 2026 05:15:00 GMT</pubDate>
      <description>Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population healthScales program footprint from 11 countries to more than 30 by 2030, including across five cities in the U.S.Builds on pilot programs that demonstrated significant increase in control rates for high blood pressure in pilot settings East Hanover, April 9, 2026 – Novartis today announced the expansion of its programs to find and treat patients with heart disease and canc</description>
    </item>
    <item>
      <title>Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%</title>
      <link>https://6ix.com/company/novartis-ag/news/novartis-igan-data-in-new-england-journal-of-medicine-show-fabhaltar-slowed-kidney-function-decline-by-493percent</link>
      <guid isPermaLink="true">https://6ix.com/company/novartis-ag/news/novartis-igan-data-in-new-england-journal-of-medicine-show-fabhaltar-slowed-kidney-function-decline-by-493percent</guid>
      <pubDate>Sun, 29 Mar 2026 05:15:00 GMT</pubDate>
      <description>Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1Fabhalta granted priority review by FDA for traditional approval Basel, March 29, 2026 – Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® (iptacopan) in IgA nephropathy (IgAN). Fabhalta demonstrated a statistically significant, clinically meaningful improvemen</description>
    </item>
    <item>
      <title>Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors</title>
      <link>https://6ix.com/company/novartis-ag/news/excellergy-to-be-acquired-by-novartis-for-up-to-usd-2-billion-to-advance-potentially-first-in-class-trifunctional-effector-cell-response-inhibitors</link>
      <guid isPermaLink="true">https://6ix.com/company/novartis-ag/news/excellergy-to-be-acquired-by-novartis-for-up-to-usd-2-billion-to-advance-potentially-first-in-class-trifunctional-effector-cell-response-inhibitors</guid>
      <pubDate>Fri, 27 Mar 2026 06:05:00 GMT</pubDate>
      <description>– Acquisition brings together Excellergy&apos;s differentiated trifunctional allergic effector cell response inhibitors (ECRIs) and the development expertise of Novartis, with a total potential transaction value of up to $2 billion – – Exl-111 is a potentially first-in-class allergic trifunctional ECRI targeting the IgE axis and is currently in Phase 1 development – PALO ALTO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Excellergy, a biotechnology company developing a novel class of allergy therapeuti</description>
    </item>
    <item>
      <title>Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation</title>
      <link>https://6ix.com/company/novartis-ag/news/novartis-agrees-to-acquire-excellergy-inc-building-on-allergy-leadership-with-next-generation-anti-ige-innovation</link>
      <guid isPermaLink="true">https://6ix.com/company/novartis-ag/news/novartis-agrees-to-acquire-excellergy-inc-building-on-allergy-leadership-with-next-generation-anti-ige-innovation</guid>
      <pubDate>Fri, 27 Mar 2026 06:00:00 GMT</pubDate>
      <description>- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed to dissociate receptor-bound IgE and drive faster, deeper pathway suppression - Exl-111 would complement existing Novartis portfolio in allergy with potential to improve both symptom control and convenience Basel, March 27, 2026 – Novartis today announced that it has entered into an agreement to ac</description>
    </item>
    <item>
      <title>Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026</title>
      <link>https://6ix.com/company/novartis-ag/news/novartis-presents-new-data-on-early-symptom-relief-and-long-term-control-in-complex-skin-diseases-at-aad-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/novartis-ag/news/novartis-presents-new-data-on-early-symptom-relief-and-long-term-control-in-complex-skin-diseases-at-aad-2026</guid>
      <pubDate>Mon, 23 Mar 2026 06:15:00 GMT</pubDate>
      <description>New Rhapsido® REMIX-1 &amp; -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presentedLong-term Cosentyx® data build on extensive body of evidence supporting continuous use in hidradenitis suppurativa (HS) and psoriasisAdditional Cosentyx data in HS include indirect comparison of efficacy and safety vs bimekizumab Basel, March 23, 2026 – Novartis will present data from more than 20 abstracts from its growing immunology portfolio at this year’s Ame</description>
    </item>
    <item>
      <title>Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline</title>
      <link>https://6ix.com/company/novartis-ag/news/novartis-agrees-to-acquire-a-pan-mutant-selective-pi3ka-inhibitor-strengthening-its-breast-cancer-pipeline</link>
      <guid isPermaLink="true">https://6ix.com/company/novartis-ag/news/novartis-agrees-to-acquire-a-pan-mutant-selective-pi3ka-inhibitor-strengthening-its-breast-cancer-pipeline</guid>
      <pubDate>Fri, 20 Mar 2026 06:00:00 GMT</pubDate>
      <description>Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818, currently in a Phase 1/2 clinical study, is designed to selectively target PI3Kα mutations in breast cancer while sparing wild-type PI3Kα, thus reducing unwanted side effects and improving tolerabilityAddresses a well‑defined patient population with significant unmet need -- approximately 40% of HR+/HER2-</description>
    </item>
    <item>
      <title>Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa</title>
      <link>https://6ix.com/company/novartis-ag/news/novartis-cosentyxr-receives-fda-approval-for-pediatric-patients-aged-12-with-moderate-to-severe-hidradenitis-suppurativa</link>
      <guid isPermaLink="true">https://6ix.com/company/novartis-ag/news/novartis-cosentyxr-receives-fda-approval-for-pediatric-patients-aged-12-with-moderate-to-severe-hidradenitis-suppurativa</guid>
      <pubDate>Fri, 13 Mar 2026 17:35:00 GMT</pubDate>
      <description>Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring importance of early diagnosis and intervention with biologics to help reduce long-term disease burden4-6 Approval marks fourth pediatric indication for Cosentyx, reinforcing its robust safety and efficacy profile1 Basel, March 13, 2026 – Novartis announced today that Cosentyx® (secukinumab) received US Food and Drug Adminis</description>
    </item>
    <item>
      <title>Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting</title>
      <link>https://6ix.com/company/novartis-ag/news/novartis-shareholders-approve-all-resolutions-proposed-by-the-board-of-directors-at-the-2026-annual-general-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/novartis-ag/news/novartis-shareholders-approve-all-resolutions-proposed-by-the-board-of-directors-at-the-2026-annual-general-meeting</guid>
      <pubDate>Fri, 06 Mar 2026 13:24:00 GMT</pubDate>
      <description>Shareholders approve 29th consecutive dividend increase to CHF 3.70 (+5.7%) per share for 2025, representing a 3.0% yield¹Shareholders confirm Giovanni Caforio as Chair of the Board of Directors as well as all other members of the Board of Directors who stood for re-election; Charles Swanton newly elected as member of the Board of DirectorsShareholders approve all other proposals by the Board of Directors, including the reduction of share capital, the 2025 report on nonfinancial matters and the</description>
    </item>
    <item>
      <title>Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy</title>
      <link>https://6ix.com/company/novartis-ag/news/novartis-successfully-completes-acquisition-of-avidity-biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-xrna-strategy</link>
      <guid isPermaLink="true">https://6ix.com/company/novartis-ag/news/novartis-successfully-completes-acquisition-of-avidity-biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-xrna-strategy</guid>
      <pubDate>Fri, 27 Feb 2026 14:00:00 GMT</pubDate>
      <description>Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks multi-billion-dollar opportunities with planned product launches before 2030Strengthens late-stage pipeline to further support 2025-2030 net sales CAGR of 5-6% cc and mid to long term growth outlook Basel, February 27, 2026 -- Novartis AG (NYSE: NVS) today announced that it has successfully completed its acqui</description>
    </item>
    <item>
      <title>Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)</title>
      <link>https://6ix.com/company/novartis-ag/news/novartis-receives-positive-chmp-opinion-for-remibrutinib-in-chronic-spontaneous-urticaria-csu</link>
      <guid isPermaLink="true">https://6ix.com/company/novartis-ag/news/novartis-receives-positive-chmp-opinion-for-remibrutinib-in-chronic-spontaneous-urticaria-csu</guid>
      <pubDate>Fri, 27 Feb 2026 11:29:00 GMT</pubDate>
      <description>Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe Improvements with remibrutinib observed as early as Week 1 in REMIX 1 &amp; 2, with favorable safety profile including no liver safety concerns through Week 521 CSU affects nearly 4 million people in Europe, with over 50% of patients remaining symptomatic despite H1-antihistamines2-4 Basel, February 27, 2026 – Novartis announced today that the Committee for Medicinal Products for Human U</description>
    </item>
    <item>
      <title>Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients</title>
      <link>https://6ix.com/company/novartis-ag/news/novartis-to-build-new-radioligand-therapy-site-in-denton-texas-delivering-more-nextgeneration-treatments-to-patients</link>
      <guid isPermaLink="true">https://6ix.com/company/novartis-ag/news/novartis-to-build-new-radioligand-therapy-site-in-denton-texas-delivering-more-nextgeneration-treatments-to-patients</guid>
      <pubDate>Wed, 25 Feb 2026 12:00:00 GMT</pubDate>
      <description>Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite to serve patients in Southern US and add network capacity as RLT expands into earlier treatment lines and additional tumor typesCompany broke ground on 4 new manufacturing and R&amp;D facilities, initiated 3 facility expansions, and announced 2 additional sites in last 10 months, rapidly making progress on its commitment to expand its US operations East Hanover, February 25, 2</description>
    </item>
    <item>
      <title>Novartis AG Enterprise Technology Report 2025: Digital Transformation Strategies, Innovation Programs, Technology Initiatives, Partnerships, Investment &amp; Acquisition, Network Map</title>
      <link>https://6ix.com/company/novartis-ag/news/novartis-ag-enterprise-technology-report-2025-digital-transformation-strategies-innovation-programs-technology-initiatives-partnerships-investment-and-acquisition-network-map</link>
      <guid isPermaLink="true">https://6ix.com/company/novartis-ag/news/novartis-ag-enterprise-technology-report-2025-digital-transformation-strategies-innovation-programs-technology-initiatives-partnerships-investment-and-acquisition-network-map</guid>
      <pubDate>Wed, 25 Feb 2026 09:07:00 GMT</pubDate>
      <description>Novartis presents key market opportunities through its focus on digital transformation, innovation programs, and strategic tech initiatives. It leverages partnerships, product launches, investments, and acquisitions to enhance its presence across therapeutic areas like oncology and immunology.Dublin, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The &quot;Enterprise Tech Ecosystem Series: Novartis AG 2025&quot; has been added to ResearchAndMarkets.com&apos;s offering. The report delves into comprehensive details of Novart</description>
    </item>
    <item>
      <title>New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer</title>
      <link>https://6ix.com/company/novartis-ag/news/new-realworld-data-reinforce-earlier-use-of-pluvictotm-before-chemotherapy-in-metastatic-castration-resistant-prostate-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/novartis-ag/news/new-realworld-data-reinforce-earlier-use-of-pluvictotm-before-chemotherapy-in-metastatic-castration-resistant-prostate-cancer</guid>
      <pubDate>Tue, 24 Feb 2026 12:15:00 GMT</pubDate>
      <description>In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPCReal‑world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI instead of multiple ARPIs A separate analysis of treatment patterns in metastatic hormone-sensitive prostate cancer suggest significant opportunity for increased guideline adherence Basel, February 24, 2026 – Novartis today announced multiple US real-world studies delivering new insights across metastatic</description>
    </item>
    <item>
      <title>Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)</title>
      <link>https://6ix.com/company/novartis-ag/news/novartis-presents-rhapsidor-remibrutinib-data-at-aaaai-showing-potential-beyond-chronic-spontaneous-urticaria-csu</link>
      <guid isPermaLink="true">https://6ix.com/company/novartis-ag/news/novartis-presents-rhapsidor-remibrutinib-data-at-aaaai-showing-potential-beyond-chronic-spontaneous-urticaria-csu</guid>
      <pubDate>Mon, 23 Feb 2026 06:15:00 GMT</pubDate>
      <description>Analyses from REMIX-1 &amp; -2 studies on CSU disease control and early symptom relief will be presented Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut allergy to be featured in an oral sessionPhase III program in food allergy (FA) planned for H2 2026 Basel, February 23, 2026 – Novartis will present data from five key abstracts evaluating the highly selective oral Bruton’s tyrosine kinase inhibitor (BTKi) Rhapsido® (remibrutinib) in chronic spontaneous u</description>
    </item>
    <item>
      <title>Unnatural Products Announces Licensing Agreement with Novartis to Develop Macrocyclic Peptide Therapeutics</title>
      <link>https://6ix.com/company/novartis-ag/news/unnatural-products-announces-licensing-agreement-with-novartis-to-develop-macrocyclic-peptide-therapeutics</link>
      <guid isPermaLink="true">https://6ix.com/company/novartis-ag/news/unnatural-products-announces-licensing-agreement-with-novartis-to-develop-macrocyclic-peptide-therapeutics</guid>
      <pubDate>Wed, 18 Feb 2026 13:00:00 GMT</pubDate>
      <description>Collaboration will harness UNP’s AI enhanced macrocycle platform to drug historically “undruggable” targetsSANTA CRUZ, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, today announced a research collaboration and licensing agreement with Novartis on an undisclosed program. The collaboration brings together UNP’s AI-enhanced macrocycle platform and Novartis’ global develo</description>
    </item>
    <item>
      <title>Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)</title>
      <link>https://6ix.com/company/novartis-ag/news/novartis-remibrutinib-first-therapy-achieve-061500638</link>
      <guid isPermaLink="true">https://6ix.com/company/novartis-ag/news/novartis-remibrutinib-first-therapy-achieve-061500638</guid>
      <pubDate>Wed, 18 Feb 2026 06:15:00 GMT</pubDate>
      <description>Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1Remibrutinib, a highly selective oral BTK inhibitor, was well-tolerated and demonstrated a favorable safety profile, including no liver safety concerns1Oral remibrutinib has potential to be first targeted therapy approved for CIndU, which affects estimated 29 million adults worldwide2,3 Basel, February 18, 2026 – Novartis today announced positive topline results from</description>
    </item>
  </channel>
</rss>